Cardiology Information System (CIS) Market by System, Component , & End User

The China cardiology information system market is projected to reach $54 million by 2024 from $35 million in 2019, at a CAGR of 8.9% during the forecast period. Growth in this market is mainly driven by the increasing incidence and prevalence of cardiovascular disease, government initiatives in China, and the increasing number of hospitals.

Integrated systems accounted for the largest share of the China cardiology information system market in 2018

On the basis of system, the China cardiology information system market is segmented into integrated and standalone systems. In 2018, integrated systems accounted for the largest share of the China cardiology market. The large share of this segment can be attributed to the increasing adoption of these systems by healthcare providers and the increasing incidence & prevalence of cardiovascular diseases.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=264168583

By component, the software segment accounted for the largest market share in 2018

On the basis of component, the China cardiology information system market is segmented into software, hardware, and service. The software segment accounted for the largest market share in 2018. This is attributed to the rising number of hospitals and the consequent increase in the demand for CVIS and CPACS, among other technologies.

L3A Hospitals are the largest end users in the China cardiology information system market

Based on end user, the China cardiology information system market is segmented into L3A, L3B, and L2 hospitals. The L3A hospitals segment accounted for the largest market share in 2018. The increasing number of L3A hospitals and the rising incidence of cardiovascular diseases in China are the major market drivers for this segment.

The key players in the China cardiology information system market are Philips Healthcare (Netherlands), CREALIFE Medical Technology (China), Central Data Network (Australia), Infinitt Healthcare (South Korea), and Esaote (Italy).

Read More@
https://www.marketsandmarkets.com/PressReleases/cardiology-information-system.asp

Anatomic Pathology Market worth $44.4 billion by 2024

The high incidence of cancer and other target diseases, availability of reimbursement, and the growing focus on personalized medicine are the major factors driving the growth of the anatomic pathology market.

The services segment accounted for the largest share of the anatomic pathology market, by product & service, in 2018

Based on product & service, the anatomic pathology market is segmented into services, consumables, and instruments. The services segment accounted for the largest share of the anatomic pathology market in 2018. The large share of this segment can be attributed to the availability of reimbursements for diagnostic tests, rapid growth in the geriatric population, and the increasing incidence of cancer and other chronic diseases.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137323145

Hospital laboratories segment to register the highest growth rate during the forecast period

Based on end user, the anatomic pathology market is segmented into hospital laboratories, clinical laboratories, and other end users. In 2018, the hospital laboratories segment accounted for the largest market share and is expected to grow at the highest CAGR during the forecast period. The growth in this market can be attributed to the increasing number of patient visits to hospitals, growing number of in-house diagnostic procedures performed in hospitals, growing awareness regarding early disease diagnosis, and the availability of reimbursements in developed markets for clinical tests performed in hospitals.

North America is the largest regional market for anatomic pathology

By region, the anatomic pathology market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018, North America accounted for the largest market share, followed by Europe. The rising prevalence of chronic diseases, increasing healthcare expenditure, the high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the region are driving the growth of the anatomic pathology market in North America.

The prominent players operating in the anatomic pathology market include F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Thermo Fisher Scientific (US), Hologic, Inc. (US), Agilent Technologies (US), Becton, Dickinson and Company (US), Sakura Finetek (Japan), Merck KGaA (Germany), Bio SB (US), Diapath S.p.A. (Italy), and BioGenex Laboratories (US).

Request Sample Pages@https://www.marketsandmarkets.com/requestsampleNew.asp?id=137323145

Emerging trends in Digital Therapeutics Market by type, revenue, industry growth and forecast 2021

The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.

According to the new market research report " Digital Therapeutics Market by Application (Prevention (Prediabetes, Obesity), Care (Diabetes, CVD, CNS, CRD, Smoking Cessation, Musculoskeletal)), Sales Channel (B2C (Patient, Caregiver), B2B (Provider, Payer, Employer, Pharma)) - Global Forecast to 2021", published by MarketsandMarkets™, The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724

The digital therapeutics market is highly fragmented, diversified, and increasingly competitive, with a large number of small players competing for market space, including startup firms.

Global Market Segmentation:

Each segment has different market players and market leaders. For instance, the prediabetes market was led by Omada in 2015. Omada Health is a leading provider of digital therapeutics for preventable type 2 diabetes and heart disease. Omada’s product portfolio consists of ‘Prevent’, an online diabetes prevention program. The company has succeeded in securing heavy investments which it channelizes into the development, enhancement, and commercialization of its product.

Based on sales channel, the digital therapeutics market is segmented into business to customer (B2C) and business to business (B2B). In 2016, the B2B segment is estimated to account for the largest share along with the highest CAGR of the digital therapeutics market. There is a growing awareness among providers, payers, and employers about the benefits provided by digital therapeutics, and the amount of healthcare cost reductions achieved by their use.

Additionally, there is a growing inclination of pharmaceutical companies to integrate digital therapeutics with their drug product to offer adherence services along with their product. These are some of the factors responsible for the high share of this market segment.

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724

What Drives the Market?

1. Increasing Incidence of Preventable Chronic Diseases
2. Rising Focus on Preventive Healthcare
3. Technological Advancements
4. Need to Control Healthcare Costs
5. Significant Increase in Venture Capital Investments
6. Benefits Offered By Digital Therapeutics

Geographical Growth Analysis:

The digital therapeutics market is segmented into North America, Europe, Asia-Pacific and the Rest of the World (RoW). In 2016, the North America is expected to dominate the market, followed by Europe. The market in North America is expected to grow at the highest CAGR during the forecast period.

Key Players and Strategies Adopted by Them:

Proteus Digital Health, Inc. (U.S.), Omada Health Inc. (U.S.), WellDoc Inc. (U.S.), Livongo Health (U.S.), Noom Inc. (U.S.), Ginger.io Inc. (U.S.), Propeller Health (U.S.), 2Morrow Inc. (U.S.), Canary Health Inc. (U.S.), Mango Health, Inc. (U.S.), and Physitrack Limited (U.K.). Click Therapeutics, Inc. (U.S.), Pear Therapeutics, Inc., (U.S.), Akili Interactive Labs, Inc. (U.S.) and Wellthy Therapeutics Pvt. Ltd (India)

Speak to Analyst @https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=51646724

Health Information Exchange Market Trends Estimates High Demand by 2020

The health information exchange market is projected to reach USD 1,545.0 million by 2020 from USD 990.6 million in 2015, at a CAGR of 9.3% during the forecast period. Federal mandates like Meaningful use, growing patient-centric approach in healthcare delivery, increasing EHR adoption rate, and need to curtail healthcare cost are some of the key factors driving the growth of market.

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249987292

Health information exchange (HIE) involves the electronic movement of health-related information among organizations according to nationally recognized standards. HIE aims to facilitate the access and retrieval of clinical data to provide safer, timelier, efficient, effective, equitable, patient -centered care. HIE enables collaboration between healthcare stakeholders, cuts down on administrative tasks, and eventually provides greater transparency in the field of healthcare. HIE is an ever-changing concept. Continuously changing technological and regulatory environment consistently evolves the HIE space.

Global Health Information Exchange Market Segmentation:

The health information exchange market has been segmented, on the basis of type, into directed exchange, query-based exchange, and consumer-mediated exchange. The directed exchange segment accounted for the largest share of the global market in 2015. Directed exchange supports point-to-point transactions and transmits documents to physicians’ EHR; this is contributing to the large share of this segment.

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=249987292

What Drives the Market?

1. Strong Government Support and Initiatives
2. Increased Measures to Improve Healthcare Quality and Care Coordination Likely to Trigger HIE Adoption
3. Need to Curtail Healthcare Costs

Geographical Growth Analysis:
The health information exchange market in Asia-Pacific is expected to grow at the fastest rate during the forecast period. High growth in this regional segment can primarily be attributed to the growing initiatives for Japan’s EHR adoption and ICT fund, investments and reforms to modernize China’s healthcare infrastructure, rapidly growing Indian healthcare industry, implementation of HCIT programs in Australia & New Zealand, and One Singaporean One Health Record - one of the pioneer patient management programs in Singapore.

Key Players and Strategies Adopted by Them:

Key players in Health Information Exchange Market include Allscripts Healthcare Solutions, Inc. (U.S.), Relayhealth Corporation (U.S.), Infor, Inc. (U.S.), Cerner Corporation (U.S.), and eClinicalWorks (U.S.) among others. These players are increasingly undertaking mergers and acquisitions, and product launches to develop and introduce new technologies and products in the market.

Speak to Analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=249987292

Non Invasive Prenatal Testing (NIPT) to Expand at a Healthy Growth Rate in the Coming Years

The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, the launch of new and advanced NIPT products, and increasing maternal age (growth in the risk of chromosomal abnormalities in babies).

Please share your specific interest to serve you better, Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690

What the Market Looks Like?

Predicted to grow at a CAGR of 13.5% during the forecast period,the global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019. The global Non Invasive Prenatal Testing (NIPT)Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.

> By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests. The cfDNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period.

> Based on application, the non-invasive prenatal testing (NIPT) market is segmented into trisomy, microdeletion syndrome, and other applications (gender identification and the detection of monogenic disorders, Klinefelter syndrome, and Rhesus (Rh) blood type).

> Based on end user, the NIPT products market is classified into diagnostic laboratories and hospitals. In 2019, diagnostic laboratories formed the largest and fastest-growing end users of NIPT products.

Get Sample Copy of This Report
@https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690

What Drives the Market?

The growth of the global market for Non Invasive Prenatal Testing (NIPT) is primarily influenced by the following factors:

• High Risk of Chromosomal Abnormalities With Increasing Maternal Age
• Growing Preference for Noninvasive Techniques Over Invasive Methods
• Improving Reimbursement Scenario for NIPT
• Programs Focusing on Increasing the Awareness of NIPT

Untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period. On the other hand, a dearth of skilled professionals is expected to restrain the growth of this market in the coming years.

Geographical growth scenario of Non Invasive Prenatal Testing (NIPT) :

Geographically, Non Invasive Prenatal Testing (NIPT) market has been studied for North America dominated the market, followed by Europe. The large share of this market can primarily be attributed to the strong economies in the US and Canada, which have allowed for significant investments in technology in this region.

Leading market players and strategies adopted

The NIPT market is diversified and highly competitive, with a large number of players competing for market space. The prominent players in the market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)

Read More: https://www.marketsandmarkets.com/PressReleases/non-invasive-prenatal-testing.asp

What is major factor of Genotyping Assay market ?

According to the new market research report "
Genotyping Assay Market by Technology (PCR, Sequencing, Microarray, Electrophoresis, MALDI-TOF), Application (Pharmacogenomics, Diagnostic Research, Animal Genetics, Agricultural Biotechnology), and Product - Global Forecast to 2023, published by MarketsandMarkets™,This study involved the extensive use of both primary and secondary sources.

The growth of this market is mainly driven by technological advancements, the decreasing prices of DNA sequencing, and the increasing incidence of genetic diseases.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595

The reagents & kits segment is expected to grow at the highest CAGR during the forecast period

Based on product, the reagents and kits are expected to grow at the highest rate during the forecast period. This segment is expected to witness the highest CAGR due to the easy accessibility of a wide range of reagents and the increasing need for genotyping in various applications.

+ Based on product, the market is divided into reagents & kits, genotyping services, instruments, and bioinformatics. The easy accessibility to a wide range of reagents and need for genotyping in various applications (such as assessing drug efficacy & safety, cutting down cost and time required for clinical development, personalizing the treatments for chronic diseases, and developing good breeds of animals and plants) have contributed to the high and repetitive consumption of reagents and kits as consumables in various genotyping applications.

+ Based on technology, the genotyping assay market is segmented into PCR, microarrays, sequencing, capillary electrophoresis, MALDI-TOF, and other technologies. The sequencing segment is expected to account for the largest share of the global genotyping market during the forecast period of 2018 to 2023.

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595

Key Players and Strategies Adopted by Them:

The genotyping market in the APAC is expected to grow at the highest CAGR during the forecast period. This is due to the increasing incidence of chronic diseases, and growing awareness on the use of genotyping tests to control the inheritance of genetic diseases and the spread of infectious and microbial diseases in APAC countries. Global pharmaceutical and biopharmaceutical companies are also increasingly outsourcing clinical research and trials to companies in this region, which has increased the demand for genotyping products for drug profile assessment, drug efficacy and safety assessment, dosing determination, and drug response evaluation.

What Drives the Market?

Thermo Fisher Scientific (US), Illumina (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US)

Autoinjectors Market Trends Estimates High Demand by 2023

According to the new market research report “Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023", published by MarketsandMarkets™, The global Autoinjectors Market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023).

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724

The key factors driving the growth of this market include the growing prevalence of targeted therapies such as rheumatoid arthritis and multiple sclerosis, rising incidence of anaphylaxis, and increasing number of regulatory approvals.

Use of autoinjectors in the treatment of rheumatoid arthritis drives the global autoinjectors market

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects connective tissues. It causes joints to swell and can result in pain, stiffness, and progressive loss of function. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US annually are affected by some form of arthritis, RA, gout, lupus, or fibromyalgia.

Global Autoinjectors Market Segmentation:

+ On the basis of type, the market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to account for the largest market share in 2017. This can primarily be attributed to their ease of use and the presence of a built-in glass syringe which makes it more convenient for patients with reduced dexterity or visual impairments.

+ On the basis of therapy, the market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, and other therapies (includes cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). The rheumatoid arthritis segment accounted for the largest share of the market in 2017. The large share of this segment is mainly attributed to the high prevalence of rheumatoid arthritis across the globe.

+ On the basis of end users, the market is segmented into home care settings and hospitals & clinics. The home care settings segment commanded the largest share of the market in 2017. The large share of this end-user segment can primarily be attributed to the rapid growth in the geriatric population across the globe and the growing need for cost-effective drug administration.

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724

What Drives the Market?

1. Growing prevalence of targeted therapies
2. Rising incidence of anaphylaxis
3. Increasing number of regulatory approvals
4. Availability of generic versions of autoinjectors

Geographical Growth Analysis:

In 2018, North America is expected to account for the largest share of the autoinjectors market, followed by Europe. Factors such as increasing geriatric population in Canada, increasing FDA approvals, rising prevalence of anaphylaxis in the US, and rising prevalence of autoimmune and chronic diseases in the US and Canada are contributing to the large share of North America.

Key Players and Strategies Adopted by Them:

The key players in the global autoinjectors market are Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US). The other prominent players in the market are J&J (US), Novartis (Switzerland), Bayer (Germany), Merck (Germany), Biogen (US), Ypsomed (Switzerland), SHL Group (Taiwan) Becton, Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), and Haselmeier (Switzerland).

What is major factor of Glycomics / Glycobiology Market ?

According to the new market research report "Glycomics / Glycobiology Market by Product (Enzymes (Glycosyltransferase, Glycosidase), Instruments (HPLS, Mass Spectrometry, MALDITOF), Kits & Reagents (Glycoproteins)), Application (Diagnostic, Drug Discovery, Oncology), End User - Global Forecast to 2021", published by MarketsandMarkets™, The global glycobiology market is expected to reach USD 1,211.4 million by 2021 from USD 649.5 million in 2016, at a CAGR of 13.3%.

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132685525

Glycobiology is the study of carbohydrates and carbohydrate-containing biomolecules in biological processes. This study is used in diagnostics, drug discovery research, immunology, oncology, and various other applications. Glycobiology products are widely used for analysis of cell surface markers, which can act as diagnostic or therapeutic targets. The base year considered for the study is 2015, and the forecast has been provided for the period between 2016 and 2021.

The following are the major objectives of the study :

1. To define, describe, and forecast the global glycobiology market on the basis of product, application, end user, and region
2. To provide detailed information regarding the major factors influencing the growth of the glycobiology market (drivers, restraints, opportunities, and industry-specific challenges)
3. To strategically analyze the micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall Glycobiology market
4. To analyze the opportunities in the market for stakeholders and to provide details of the competitive landscape for market leaders
5. To forecast the Glycobiology market size of the market segments with respect to four main regional segments, namely, North America, Europe, Asia, and the Rest of the World
6. To strategically profile the key players and comprehensively analyze their market shares and core competencies2
7. To track and analyze the competitive developments such as new product launches, agreements, collaborations, acquisitions, expansion and agreements in the glycomics market

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132685525

Key Players and Strategies Adopted by Them:

The key players in the glycobiology market include Agilent Technologies (U.S.), Bruker Corporation (U.S.), Danaher Corporation (U.S.), New England Biolabs (U.S.), ProZyme, Inc. (U.S.), Shimadzu Corporation (Japan), Merck KGaA (Germany), Takara Bio, Inc. (Japan), Thermo Fisher Scientific (U.S.), and Waters Corporation (U.S.).

Oncology :

Glycomics plays a crucial role in analyzing the molecular mechanism of various types of cancers. Glycomics also plays an important role in identifying new biomarkers for cancers. Biomarkers are used as key diagnostic targets for various types of cancers. They can also be used for devising novel and personalized therapies for cancer patients. Owing to its ability to differentiate between protein sub-types based on the molecular structure of their glycan patterns, glycomics has emerged as an important research tool for the discovery and validation of protein-based cancer biomarkers.

What is major factor of Genotyping Assay market ?

According to the new market research report "
Genotyping Assay Market by Technology (PCR, Sequencing, Microarray, Electrophoresis, MALDI-TOF), Application (Pharmacogenomics, Diagnostic Research, Animal Genetics, Agricultural Biotechnology), and Product - Global Forecast to 2023, published by MarketsandMarkets™,This study involved the extensive use of both primary and secondary sources.

The growth of this market is mainly driven by technological advancements, the decreasing prices of DNA sequencing, and the increasing incidence of genetic diseases.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595

The reagents & kits segment is expected to grow at the highest CAGR during the forecast period
Based on product, the reagents and kits are expected to grow at the highest rate during the forecast period. This segment is expected to witness the highest CAGR due to the easy accessibility of a wide range of reagents and the increasing need for genotyping in various applications.

+ Based on product, the market is divided into reagents & kits, genotyping services, instruments, and bioinformatics. The easy accessibility to a wide range of reagents and need for genotyping in various applications (such as assessing drug efficacy & safety, cutting down cost and time required for clinical development, personalizing the treatments for chronic diseases, and developing good breeds of animals and plants) have contributed to the high and repetitive consumption of reagents and kits as consumables in various genotyping applications.

+ Based on technology, the genotyping assay market is segmented into PCR, microarrays, sequencing, capillary electrophoresis, MALDI-TOF, and other technologies. The sequencing segment is expected to account for the largest share of the global genotyping market during the forecast period of 2018 to 2023.

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595

Key Players and Strategies Adopted by Them:

The genotyping market in the APAC is expected to grow at the highest CAGR during the forecast period. This is due to the increasing incidence of chronic diseases, and growing awareness on the use of genotyping tests to control the inheritance of genetic diseases and the spread of infectious and microbial diseases in APAC countries. Global pharmaceutical and biopharmaceutical companies are also increasingly outsourcing clinical research and trials to companies in this region, which has increased the demand for genotyping products for drug profile assessment, drug efficacy and safety assessment, dosing determination, and drug response evaluation.

What Drives the Market?

Thermo Fisher Scientific (US), Illumina (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US)

Useful Analysis from Experts on Infectious Disease Diagnostics Market

The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%. The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022. Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

Global Market Segmentation:

The market is broadly segmented into assays, kits, & reagents; instruments; and services & software based on product & service. The assays, kits, & reagents segment accounted for the largest share of the global market and is expected to register the highest CAGR during the forecast period. The increasing number of infectious disease diagnostic tests carried out; easy accessibility to a wide range of reagents; and the growing need for reliable, specific, and faster detection of infectious diseases in the early stages are the key factors driving the IDD assays, kits, & reagents market.

Based on the disease type, the market is segmented into hepatitis, HIV, HAIs, CT/NG, HPV, TB, Influenza, and other diseases. The hepatitis diagnostics segment accounted for the largest share of the global market in 2017. The dominant share of this segment can be attributed to the rising prevalence of hepatitis B and C, the availability of a large number of hepatitis diagnostic tests, and increasing number of HIV/Hepatitis co-infections.

The infectious disease diagnostics market is segmented into major seven technologies, namely, immunodiagnostics, clinical microbiology, PCR, INAAT, DNA sequencing & NGS, DNA microarrays, and other technologies. In 2017, the immunodiagnostics segment accounted for the largest share of the global market. The large share of this segment can be attributed to the increasing use of immunoassays in POC infectious disease testing, development of novel tests, rising trend of automation, and increasing awareness about health and fitness.

On the basis of end user, the global market is segmented into hospitals/clinical laboratories, reference laboratories, physician offices, academic/research institutes, and other end users. In 2017, the hospitals/clinical laboratories segment accounted for the largest share of the global market. Also, this segment is expected to grow at the highest CAGR during the forecast period due to the large number of diagnostic tests carried out in hospitals.

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

What Drives the Market?

Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics

Geographical Growth Analysis:
North America accounted for the largest share of the global market. This large share can be attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.

Some of The Major Players In infectious disease diagnostics :
1. Proteus Digital Health, Inc. (U.S.)
2. Omada Health Inc. (U.S.)
3. WellDoc Inc. (U.S.)
4. Livongo Health (U.S.)
5 Noom Inc. (U.S.)
6. Ginger.io Inc. (U.S.), etc.

Pedicle Screw Systems Market worth $724.23 million by 2023

 According to the new market research report “Pedicle Screw System Market by Product Type (Monoaxial & Polyaxial Pedicle Screw), Surgery (Open Surgery, Minimal Invasive Surgery), Indication (Spinal Deformities, Spinal Trauma), Application (Thoracolumbar, Cervical Fusion) - Global Forecast to 2023", published by MarketsandMarkets™, The pedicle screw systems market is expected to reach USD 724.23 million by 2023 from USD 538.64 million in 2018, at a CAGR of 6.1%.

Get 10% Free Customization on report @
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=98811670

The major factors driving the growth of this market are the increasing incidence of spinal cord injuries, the growing preference for minimally invasive surgeries, and a rising geriatric population.
By product type, the pedicle screw systems market is segmented into monoaxial, polyaxial, and other pedicle screw systems. In 2018, the polyaxial pedicle screw systems segment is estimated to command the largest share of the pedicle screw systems market. The large share of this segment can be attributed to the increasing incidences and prevalence of spinal cord injuries.

Download the PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=98811670

Browse and in-depth TOC on “Pedicle Screw Systems Market”
66 - Tables

36 - Figures

110 - Pages

To get Bundle Reports @
https://www.marketsandmarkets.com/RequestBundleReport.asp?id=98811670

Stringent regulatory frameworks and time-consuming product approval processes may hinder the growth of the pedicle screw systems market to a certain extent.

The major players in the pedicle screw systems market include Globus Medical (US), DePuy Synthes (US), Zimmer Biomet (US), B. Braun (US), Stryker (US), and Medtronic (Ireland).

Useful Analysis from Experts on Drug Screening Market

The drug screening market was valued at USD 4.86 Billion in 2016 and is expected to reach USD 8.63 Billion by 2022, growing at a CAGR of 10.2% during the forecast period. The base year considered for the study is 2016 and the forecast period is from 2017 to 2022.

The report "Drug Screening Market by Product ((Immunoassay Analyzer, Chromatography, Breathalyzer, Rapid Test Device, Assay Kits)), Drug Screening Services, Sample Type (Urine, Hair, Oral), End User (Workplace, Criminal Justice, Hospital) - Global Forecast to 2022", The drug screening market is expected to reach USD 8.63 Billion by 2022 from USD 5.32 Billion in 2017, at a CAGR of 10.2%. This high growth rate is attributed to factors such as growing drug and alcohol consumption; government funding in major markets, enforcement of stringent laws mandating drug and alcohol testing, and regulatory approvals and new product and service launches.

Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773

Global Market Segmentation:
The report segments the global market by product and service, sample type, end user, and region.

Based on product, the market is segmented into analytical instruments, rapid testing devices, and consumables. Rapid testing devices market is further subsegmented into urine testing devices and oral fluid testing devices. The urine testing devices segment is expected to account for the largest market share in 2017. However, the oral fluid testing devices segment is projected to register highest CAGR during the forecast period. The high growth in this segment is attributed to the benefits it offers such as shorter detection window, non-invasive nature, and low risk of sample tampering.

The global market by sample type is segmented into urine, breath, oral fluid, hair, and other samples. The urine sample segment is estimated to account for the largest share in 2017, however, the oral fluid samples segment is expected to register the highest growth rate during the forecast period.

Based on end users, the market is segmented into workplaces, criminal justice systems and law enforcement, drug treatment centers, pain management centers, schools and colleges, hospitals, individual users, and drug testing laboratories. In 2017, the workplace testing segment is expected to account for the largest share of the market. The growth of this end-user segment can be attributed to the growing safety concerns in the workplace and the increasing number of organizations that have made regular drug screening mandatory.

Get Expert Analysis and Insights of Global Market | Request Sample Report:https://www.marketsandmarkets.com/requestsampleNew.asp?id=162987773

What Drives the Market?
1. Growing Drug & Alcohol Consumption
2. Enforcement of Stringent Laws Mandating Drug and Alcohol Testing
3. Presence of Government Funding in Major Markets
4. Regulatory Approvals & Product Launches and Services

Geographical Growth Analysis:

The market is dominated by North America, followed by Europe, Asia Pacific, and the Rest of the World (RoW). The dominance of the North American market is attributed to factors such as rising consumption of illicit drugs, availability of government funding to curb drug abuse, and the presence of laws supporting drug screening, and growing burden of accidents due to unsafe levels of alcohol consumption.

Key Players and Strategies Adopted by Them:

Alere (US), Thermo Fisher (US), Drägerwerk (Germany), OraSure (US), Alfa Scientific Designs (US), Lifeloc (US), MPD, Inc. (US), Premier Biotech (US), Shimadzu (Japan), Siemens Healthineers (US). While, LabCorp (US), Quest Diagnostics (US), Omega Laboratories (US), Psychemedics (US), CRL (US), SureHire (Canada), and CannAmm (Canada) are some of key players offering drug screening services.

Speak to Analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=162987773